Abstract
Injection of type 6b pneumococci into pigs results in a sharp rise in levels of interleukin-6 (IL-6) in blood, with an average peak value of 7,700 U/ml at 4 h and mortality in five of seven of these animals. Pretreatment at -24 h with the monocyte activator MTP-PE prevents this strong increase in IL-6 (peak value, 1,000 U/ml) and reduces mortality to zero of six animals. This suggests that MTP-PE, in addition to activating monocytes, protects animals by preventing the harmful increase of cytokines such as IL-6.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylmuramyl-Alanyl-Isoglutamine / administration & dosage
-
Acetylmuramyl-Alanyl-Isoglutamine / analogs & derivatives*
-
Acetylmuramyl-Alanyl-Isoglutamine / pharmacology
-
Acetylmuramyl-Alanyl-Isoglutamine / therapeutic use
-
Adjuvants, Immunologic / administration & dosage
-
Adjuvants, Immunologic / pharmacology*
-
Adjuvants, Immunologic / therapeutic use
-
Animals
-
Bacteremia / prevention & control*
-
Injections, Intravenous
-
Interleukin-6 / biosynthesis
-
Interleukin-6 / immunology*
-
Liposomes
-
Monocytes / drug effects
-
Monocytes / metabolism
-
Phosphatidylethanolamines / administration & dosage
-
Phosphatidylethanolamines / pharmacology*
-
Phosphatidylethanolamines / therapeutic use
-
Pneumococcal Infections / prevention & control*
-
Swine
Substances
-
Adjuvants, Immunologic
-
Interleukin-6
-
Liposomes
-
Phosphatidylethanolamines
-
mifamurtide
-
Acetylmuramyl-Alanyl-Isoglutamine